Seroprevalence and protective effect of SARS-CoV-2 immunity against symptomatic SARS-CoV-2 infection among children and adolescents in Nakhon Phanom province, Thailand 2024 – 2025
Keywords:
Seroprevalence, SARs-CoV-2 immunity, Protective effect, Children and adolescentsAbstract
Background : The Omicron variants have altered the epidemiology of COVID-19, particularly among children and adolescent , who commonly experience mild or asymptomatic infection but may still contribute to community transmission. Understanding population-level immunity in this age group is important for guiding public health strategies.This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies and to to assess the association between baseline seropositivity and the risk of symptomatic SARS-CoV-2 infection among children and adolescents in Nakhon Phanom province, Thailand. Methods : A population-based prospective cohort study was conducted aming children and adolescents aged 6 months to 17 years using stratified random sampling by age group. A total of 999 participants were enrolled. Blood samples were collected at enrollement, 6 months, and 12 months to measure anti-S and anti-N SARS-CoV-2 IgG antibodies using ELISA.. Participants were followed weekly for COVID-19–like illness, and symptomatic infections were confirmed by multiplex reverse transcription polymerase chain reaction (multiplex RT-PCR). Cox proportional hazards regression was used to evaluate the association between baseline anti-S IgG seropositivity and the risk of symptomatic SARS-CoV-2 infection, adjusting for relevant confounders. Results : The mean age of participants was 8.1 years and 53.3% had received at least one dose of COVID-19 vaccine. Anti-S IgG seropositivity exceeded 80% in all age throughout the 12-month follow-up. During follow-up, 439 episodes of COVID-like illness were reported, of which 32 were confirmed SARS-CoV-2 infections. Baseline anti-S IgG seropositivity was associated with a lower risk of symptomatic SARS-CoV-2 infection (Hazard Ratio: 0.64; 95% confidence interval 0.23–1.81), corresponding to a protective effect of 36%, although the association was notstatistical significance. Conclusions : Children and adolescents in Nakhon Phanom province exhibited a high seroprevalence of SARS-CoV-2 antibodies throughout the study period. Baseline seropositivity showed a non-significant trend toward reduced risk ofsymptomatic SARS-CoV-2 infection. These findings highlight the importance ofcontinued surveillance and targeted vaccination strategies focusing on high-risk pediatric and adolescentspopulations.References
Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S, Wongboot W, et al. Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020. Vol. 25, Eurosurveillance. 2020.https://doi.org/10.2807/1560-7917.ES.2020.25.8.2000097
Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K, et al. Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022. Arch Virol. 2023;168(1).https://doi.org/10.1007/s00705-022-05666-6
Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S, Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand. Adv Prev Med. 2021;2021.https://doi.org/10.1155/2021/5807056
Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Vol. 7, Signal Transduction and Targeted Therapy. 2022. https://doi.org/10.1038/s41392-022-01039-2
Romanchuk LI, Koloskova OK. PECULIARITIES OF THE CORONAVIRUS INFECTION CLINICAL COURSE CAUSED BY SARS-COV2 IN CHILDREN POPULATION (LITERARY REVIEW). Clin Exp Pathol. 2024;22(4). https://doi.org/10.24061/1727-4338.XXII.4.86.2023.09
Coffin SE, Rubin D. Yes, Children Can Transmit COVID, but We Need Not Fear. Vol. 175, JAMA Pediatrics. 2021. https://doi.org/10.1001/jamapediatrics.2021.2767
Paul LA, Daneman N, Schwartz KL, Science M, Brown KA, Whelan M, et al. Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. JAMA Pediatr. 2021;175(11). https://doi.org/10.1001/jamapediatrics.2021.2770
สำนักสื่อสารความเสี่ยงและพฤติกรรม. https://ddc.moph.go.th/brc/news.php?news=40060&deptcode=brc. 2024. ผลกระทบของวัคซีนโควิด 19 และข้อมูลการเฝ้าระวังเหตุการณ์ไม่พึงประสงค์ที่เกิดภายหลังการได้รับวัคซีน.
สมาคมโรคติดเชื้อเด็กแห่งประเทศไทย. https://www.pidst.net/A1524.html. 2568. คําแนะนําการฉีดวัคซีนป้องกันโรคโควิด-19 สําหรับเด็กและวัยรุ่น ฉบับที่ 13.
Lorenz E, Souares A, Amuasi J, Loag W, Deschermeier C, Fusco D, et al. Seroprevalence of SARS-CoV-2 in urban settings in three sub-Saharan African countries (SeroCoV): A study protocol for a household-based cross-sectional prevalence study using two-stage cluster sampling. BMJ Open. 2021;11(12). https://doi.org/10.1136/bmjopen-2021-056853
Clarke KEN, Kim Y, Jones J, Lee A, Deng Y, Nycz E, et al. Pediatric Infection-Induced SARS-CoV-2 Seroprevalence Increases and Seroprevalence by Type of Clinical Care-September 2021 to February 2022. Journal of Infectious Diseases. 2023;227(3).https://doi.org/10.1093/infdis/jiac423
World Health Organization. https://www.who.int/westernpacific/emergencies/covid-19/information/asymptomatic-covid-19. 2023. COVID-19: symptoms.
QIAGEN. https://www.qiagen.com/ca/products/diagnostics-and-clinical-research/infectious-disease/qiastat-dx-syndromic-testing/qiastat-dx-ca. 2025. QIAstat-Dx Respiratory SARS-CoV-2 Panel.
Barouch DH. Covid-19 Vaccines - Immunity, Variants, Boosters. New England Journal of Medicine. 2022;387(11). https://doi.org/10.1056/NEJMra2206573
Movsisyan M, Chopikyan A, Kasparova I, Hakobjanyan G, Carrat F, Sukiasyan M, et al. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients. Sci Rep. 2022;12(1). https://doi.org/10.1038/s41598-022-16402-0
Abdullahi A, Frimpong J, Cheng MTK, Aliyu SH, Smith C, Abimiku A, et al. Performance of SARS COV-2 IgG Anti-N as an Independent Marker of Exposure to SARS COV-2 in an Unvaccinated West African Population. American Journal of Tropical Medicine and Hygiene. 2023;109(4). https://doi.org/10.4269/ajtmh.23-0179
Suntronwong N, Vichaiwattana P, Klinfueng S, Puenpa J, Kanokudom S, Assawakosri S, et al. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study. PLoS One. 2023;18(4 April).
https://doi.org/10.1371/journal.pone.0279147
Department of Medical Sciences Ministry of Public Health. https://www.dmsc.moph.go.th/th/detailAll/2997/nw/25. 2568. กรมวิทย์ฯ เฝ้าระวังสายพันธุ์โควิด 19 พบโอมิครอนสายพันธุ์ JN.1 ยังเป็นสายพันธุ์หลักในไทย.
Hart JD, Ong DS, Chokephaibulkit K, Ong-Lim AT, Vereti I, Crawford NW, et al. Considerations for vaccinating children against COVID-19. Vol. 7, BMJ Paediatrics Open. 2023. https://doi.org/10.1136/bmjpo-2023-001964
Chantasrisawad N, Puthanakit T, Tangsathapornpong A, Techasaensiri C, Phongsamart W, Suwanpakdee D, et al. Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. Vaccines (Basel). 2022;10(6).https://doi.org/10.3390/vaccines10060871
Suryawanshi YN, Biswas DA. Herd Immunity to Fight Against COVID-19: A Narrative Review. Cureus. 2023. https://doi.org/10.7759/cureus.33575
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nakhonphanom Hospital Journal

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
- บทความที่ได้รับการตีพิมพ์ถือเป็นลิขสิทธิ์ของ โรงพยาบาลนครพนม
- ข้อความหรือข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความนั้นๆ ไม่ใช่ความเห็นของกองบรรณาธิการ